Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Candidiasis Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Candidiasis Overview | 14 | 1 |
| Pipeline Products for Candidiasis Comparative Analysis | 15 | 1 |
| Candidiasis Therapeutics under Development by Companies | 16 | 2 |
| Candidiasis Therapeutics under Investigation by Universities/Institutes | 18 | 2 |
| Candidiasis Pipeline Products Glance | 20 | 4 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Unknown Stage Products | 23 | 1 |
| Candidiasis Products under Development by Companies | 24 | 3 |
| Candidiasis Products under Investigation by Universities/Institutes | 27 | 1 |
| Candidiasis Companies Involved in Therapeutics Development | 28 | 22 |
| Amplyx Pharmaceuticals, Inc. | 28 | 1 |
| Bakker Medical Srl | 29 | 1 |
| Biomar Microbial Technologies | 30 | 1 |
| Biosergen AS | 31 | 1 |
| Cellceutix Corporation | 32 | 1 |
| Cidara Therapeutics, Inc. | 33 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 34 | 1 |
| Dermala Inc | 35 | 1 |
| General Biologicals Corporation | 36 | 1 |
| Grupo Ferrer Internacional, S.A. | 37 | 1 |
| Hsiri Therapeutics, LLC | 38 | 1 |
| iCo Therapeutics Inc. | 39 | 1 |
| Matinas BioPharma Holdings, Inc. | 40 | 1 |
| Nanomerics Ltd | 41 | 1 |
| Novabiotics Limited | 42 | 1 |
| NovaDigm Therapeutics, Inc. | 43 | 1 |
| Onxeo SA | 44 | 1 |
| Scynexis, Inc. | 45 | 1 |
| Sealife PHARMA GMBH | 46 | 1 |
| TGV-Laboratories | 47 | 1 |
| Viamet Pharmaceuticals, Inc. | 48 | 1 |
| Wellstat Vaccines, LLC | 49 | 1 |
| Candidiasis Therapeutics Assessment | 50 | 10 |
| Assessment by Monotherapy Products | 50 | 1 |
| Assessment by Combination Products | 51 | 1 |
| Assessment by Target | 52 | 2 |
| Assessment by Mechanism of Action | 54 | 2 |
| Assessment by Route of Administration | 56 | 2 |
| Assessment by Molecule Type | 58 | 2 |
| Drug Profiles | 60 | 74 |
| (clotrimazole + diclofenac sodium) Drug Profile | 60 | 1 |
| (clotrimazole + diclofenac sodium) 1 Drug Profile | 61 | 1 |
| 61894700 Drug Profile | 62 | 1 |
| AC-17 Drug Profile | 63 | 1 |
| amphotericin B Drug Profile | 64 | 2 |
| amphotericin B Drug Profile | 66 | 3 |
| amphotericin B Drug Profile | 69 | 1 |
| Antibody to Target Ece1 for Candidiasis Drug Profile | 70 | 1 |
| APX-001 Drug Profile | 71 | 1 |
| arasertaconazole Drug Profile | 72 | 1 |
| BSG-005 Drug Profile | 73 | 1 |
| candidiasis vaccine Drug Profile | 74 | 1 |
| CD-101 Drug Profile | 75 | 3 |
| Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile | 78 | 1 |
| CTIX-1502 Drug Profile | 79 | 1 |
| Drug for Candidiasis Drug Profile | 80 | 1 |
| DWP-06081 Drug Profile | 81 | 1 |
| Forazoline A Drug Profile | 82 | 1 |
| iCo-010 Drug Profile | 83 | 1 |
| KSL-W Drug Profile | 84 | 1 |
| MH-010 Drug Profile | 85 | 1 |
| miconazole nitrate Drug Profile | 86 | 2 |
| Monoclonal Antibodies for Candidiasis Drug Profile | 88 | 1 |
| Monoclonal Antibody for Candidiasis Drug Profile | 89 | 1 |
| Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections Drug Profile | 90 | 1 |
| Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections Drug Profile | 91 | 1 |
| mutanobactins Drug Profile | 92 | 1 |
| Myc-102 Drug Profile | 93 | 1 |
| NDV-3 Drug Profile | 94 | 2 |
| NDV-3A Drug Profile | 96 | 1 |
| NP-339 Drug Profile | 97 | 1 |
| obliquumol Drug Profile | 98 | 1 |
| Occidiofungin Drug Profile | 99 | 1 |
| PAC-113 Drug Profile | 100 | 2 |
| PMX-1408 Drug Profile | 102 | 1 |
| PMX-1570 Drug Profile | 103 | 1 |
| PMX-1576 Drug Profile | 104 | 1 |
| PMX-1591 Drug Profile | 105 | 1 |
| PMX-1625 Drug Profile | 106 | 1 |
| PMX-519 Drug Profile | 107 | 1 |
| PMX-70004 Drug Profile | 108 | 1 |
| Recombinant Peptides for Oropharyngeal Candidiasis Drug Profile | 109 | 1 |
| SCY-078 Drug Profile | 110 | 3 |
| SLP-0901 Drug Profile | 113 | 1 |
| SLP-0904 Drug Profile | 114 | 1 |
| Small Molecule for Bacterial Vaginosis and Candidiasis Drug Profile | 115 | 1 |
| Small Molecule for Fungal Infections Drug Profile | 116 | 1 |
| Small Molecules for Aspergillosis and Candidiasis Drug Profile | 117 | 1 |
| Small Molecules for Candidiasis Drug Profile | 118 | 1 |
| Small Molecules for Candidiasis Drug Profile | 119 | 1 |
| Small Molecules for Candidiasis Drug Profile | 120 | 1 |
| Small Molecules for Fungal Infections Drug Profile | 121 | 1 |
| Small Molecules for Fungal Infections Drug Profile | 122 | 1 |
| Small Molecules for Systemic Candidiasis Drug Profile | 123 | 1 |
| Synthetic Peptide to Inhibit CBL-B for Candidiasis Drug Profile | 124 | 1 |
| Synthetic Peptides for Candidiasis Drug Profile | 125 | 1 |
| Synthetic Peptides for Infections Diseases and Oncology Drug Profile | 126 | 1 |
| TOL-463 Drug Profile | 127 | 1 |
| Vaccine for Fungal Infections Drug Profile | 128 | 1 |
| Vaccine to Target Ece1 for Candidiasis Drug Profile | 129 | 1 |
| VT-1161 Drug Profile | 130 | 4 |
| Candidiasis Dormant Projects | 134 | 4 |
| Candidiasis Discontinued Products | 138 | 1 |
| Candidiasis Product Development Milestones | 139 | 11 |
| Featured News &Press Releases | 139 | 1 |
| Jun 20, 2016: SCYNEXIS Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections | 139 | 1 |
| Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH | 139 | 2 |
| Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections | 141 | 1 |
| Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis | 142 | 1 |
| Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 | 142 | 1 |
| Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors | 143 | 1 |
| May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate | 144 | 1 |
| May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors | 145 | 1 |
| May 13, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections | 146 | 1 |
| Apr 15, 2016: SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis | 146 | 1 |
| Apr 06, 2016: SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis | 147 | 1 |
| Mar 10, 2016: Matinas BioPharma to Present an update on MAT2203 and to Present at the 28th Annual ROTH Conference | 148 | 1 |
| Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis | 148 | 1 |
| Feb 08, 2016: Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B | 149 | 1 |
| Appendix | 150 | 2 |
| Methodology | 150 | 1 |
| Coverage | 150 | 1 |
| Secondary Research | 150 | 1 |
| Primary Research | 150 | 1 |
| Expert Panel Validation | 150 | 1 |
| Contact Us | 150 | 1 |
| Disclaimer | 151 | 1 |